Barclays’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-2,001
| Closed | -$8K | – | 5604 |
|
|
2025
Q2 | $8K | Sell |
2,001
-60,302
| -97% | -$149K | ﹤0.01% | 4931 |
|
|
2025
Q1 | $56.7K | Sell |
62,303
-29,331
| -32% | -$40.7K | ﹤0.01% | 4586 |
|
|
2024
Q4 | $254K | Buy |
91,634
+14,904
| +19% | +$56.7K | ﹤0.01% | 4196 |
|
|
2024
Q3 | $401K | Buy |
76,730
+55,497
| +261% | +$288K | ﹤0.01% | 3909 |
|
|
2024
Q2 | $94.7K | Sell |
21,233
-15,676
| -42% | -$76K | ﹤0.01% | 3935 |
|
|
2024
Q1 | $283K | Sell |
36,909
-32,215
| -47% | -$177K | ﹤0.01% | 3925 |
|
|
2023
Q4 | $294K | Buy |
69,124
+59,904
| +650% | +$213K | ﹤0.01% | 4221 |
|
|
2023
Q3 | $38.7K | Sell |
9,220
-985
| -10% | -$5.01K | ﹤0.01% | 3969 |
|
|
2023
Q2 | $56.8K | Buy |
10,205
+3,932
| +63% | +$23.2K | ﹤0.01% | 3780 |
|
|
2023
Q1 | $35.9K | Hold |
6,273
| – | – | ﹤0.01% | 4521 |
|
|
2022
Q4 | $6.59K | Sell |
6,273
-130
| -2% | -$227 | ﹤0.01% | 4969 |
|
|
2022
Q3 | $17K | Hold |
6,403
| – | – | ﹤0.01% | 4118 |
|
|
2022
Q2 | $31K | Sell |
6,403
-2,337
| -27% | -$10.2K | ﹤0.01% | 4230 |
|
|
2022
Q1 | $36K | Buy |
+8,740
| New | +$51.4K | ﹤0.01% | 4240 |
|
Barclays's INZY Position: Q3 2025 in Review
Barclays sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 2,001 shares — an estimated $8K sold.
Barclays first reported a position in INZY in Q1 2022 and held it in 14 quarters. The position peaked at $401K in Q3 2024. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- Barclays reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- Barclays sold 2,001 Inozyme Pharma shares in Q3 2025, an estimated $8K.
- Barclays first reported a position in Inozyme Pharma in Q1 2022 and held it in 14 quarters.
- Barclays's Inozyme Pharma position peaked at $401K in Q3 2024.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.